期刊文献+

抗SARS-CoV免疫球蛋白乳酸-羟乙酸共聚物微球的制备与性质 被引量:1

Preparation and characteristics of anti-SARS-CoV immunoglobulin poly (lactide-co-glycolide acid) microspheres
下载PDF
导出
摘要 目的制备抗SARS-CoV免疫球蛋白(ASI)乳酸-羟乙酸共聚物(PLGA)微球,研究其体外释放性质及中和SARS活性。方法采用复乳溶剂挥发法制备ASI微球,以激光粒度测定仪测定微球的平均粒径,以BCA法及微量BCA法测定微球的蛋白含量及蛋白从微球的释放。用ELISA法考察从微球中释放出的ASI的活性。结果ASI微球粒径均匀,平均粒径为15.87 μm,蛋白包裹率为70.1%,载药量为6.3%,微球中包裹的ASI与原蛋白溶液相比活性不损失。结论采用复乳溶剂挥发法,通过控制一定的因素,可以得到具有较高包封率的ASI微球。 OBJECTIVE To prepare Anti-SARS-CoV immanoglobulinn (ASI) PLGA microspheres and to study on the release characteristics in vitro and the activity of neutralization of ASI on SARS virus. METHODS The microspheres were prepared by using (water-in-oil)- inwater emulsion solvent evaporation technique. The microspheres diameter was determined by laser particle sizer. The concentration of ASI and the release of ASI from microspheres were measured by BCA and micro BCA method. The neutralization activity of ASI release from microspheres was evaluated by ELISA method.RESULTS ASI microspheres were homogeneous with the average diameter of 15.87 μm,the encapsulation of protein was 70.1% and protein content was 6.3%, the activity of ASI release from microspheres was maiteined. CONCLUSION The microspheres containing relatively high concentration of ASI can be produced by controling different process.
出处 《中国药学杂志》 EI CAS CSCD 北大核心 2005年第14期1077-1079,共3页 Chinese Pharmaceutical Journal
关键词 抗SARS-CoV免疫球蛋白 生物可降解性微球 乳酸-羟乙酸共聚物 溶剂挥发法 anti- SARS- CoV immunoglobulin biodegradable microspheres poly ( lactide- co-glycolide acid) solvent evaporation
  • 引文网络
  • 相关文献

参考文献4

二级参考文献17

  • 1Stephensen CB, CaseBolt DB, Gangopadhyay NN. Phylogenetic analysis of a highly conserved region of the polymerase gene from 11 coronaviruses and development of a consensus polymerase chain reaction assay. Virus Res, 1999,60:181 - 189.
  • 2Vabret A, Mouthon F, Mourez T, Gouarin S, Petitjean J, Freymuth F. Direct diagnosis of human respiratory coronaviruses 229E and OC 43 by the polymerase chain reaction.J Virol Methods,2001,97:59-66.
  • 3Poutanen SM, Low DE, Henry B, Finkelstein S, Rose D, Green K,Tellier R, Draker R, Adachi D, Ayers M, Chan AK, Skowronski DM,Salit I, Simor AE, Slutsky AS, Doyle PW, Krajden M, Petric M, Brunham RC, McGeer AJ. Identification of severe acute respiratory syndrome in Canada. N Engl J Med. Low-1 - low-11 (at www.nejm.org on March 31,2003).
  • 4Mao Z D,实验统计学,1998年,232页
  • 5Lu B,药物新剂型与新技术,1998年,281页
  • 6Chen X P,New Edit Pharmaceutics(第14版),1997年,95,125页
  • 7Lee,N,Hui,D,Wu,A. et al.A major outbreak of severe acute respiratory syndrome inHongKong[].The New England Journal of Medicine.
  • 8.VirusTaxonomy[]..2001
  • 9Uchil,P.D,Satchidanandam,V.Characterization ofRNA synthesis, replication mechanism, and in vitroRNA-dependentRNA polymerase activity ofJapanese encephalitis virus[].Journal of Virology.2003
  • 10Henkel,J.Attacking AIDS with a揷ocktail?therapy?[].FDA Consumer.1999

共引文献222

同被引文献25

  • 1钟延强,周永刚,张国庆,傅强,王彬,龚纯贵,鲁莹,高申.局部麻醉用缓释盐酸布比卡因PLGA微球的制备及特性研究[J].第二军医大学学报,2004,25(8):865-868. 被引量:5
  • 2陈善,李萍,丁建新,陶胜源,窦媛媛,王希良,王洪权.牛血清白蛋白乳酸-羟乙酸共聚物微球的制备[J].解放军药学学报,2005,21(2):96-100. 被引量:5
  • 3朱艳,鲁莹,陈文娅,钟延强.胸腺肽α_1微球的制备及其评价[J].药学服务与研究,2005,5(3):248-250. 被引量:3
  • 4叶美娣,郑彩虹.乳酸-羟基乙酸共聚物(PLGA)微球控释系统的突释[J].中国现代应用药学,2005,22(5):371-374. 被引量:9
  • 5滕彦,梁文权,林季建,郑晓玲.玻璃体内注射用地塞米松微球的制备[J].中国现代应用药学,2005,22(5):393-395. 被引量:2
  • 6Fang-I.Liu,J.H.Kuo,K.C.Sung,et al.Biodegradable polymeric microspheres for nalbuphine prodrug controlled delivery:in vitro characterization and in vivo pharmacokinetic studies.International Journal of Pharmaceutics,2003,257:23~31.
  • 7Maria J.Blanco-Prieto,Kamel Besseghir,Oliver Zerbe,et al.In vitro and in vivo evaluation of a somatostatin analogue released from PLGA microspheres.Journal of Controlled Release,2000,67:19~28.
  • 8Michael Abazingea,Tanise Jacksonb,Qing Yang,et al.In vitro and in vivo characterization of biodegradable enoxacin microspheres.European Journal of Pharmaceutics and Biopharmaceutics,2000,49:191~194.
  • 9M.Tuncay,S.Calis,H.S.Kas,et al.Diclofenac sodium incorporated PLGA (50:50) microspheres:formulation considerations and in vitro/in vivo evaluation.International Journal of Pharmaceutics,2000,195:179~188.
  • 10Carmen Evora,Isabel Soriano,Rick A.Rogers,et al.Relating the phagocytosis of microparticles by alveolar macrophages to surface chemistry:the effect of 1,2-dipalmitoylphosphatidylcholine.Journal of Controlled Release,1998,51:143~152.

引证文献1

二级引证文献7

;
使用帮助 返回顶部